LUTZ, Fla.--(BUSINESS WIRE)--CytoDyn Inc. (the “Company”) (OTC:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has entered into a consulting arrangement with SDG, LLC (“SDG”), a regulatory advisory service firm located in Cambridge, Massachusetts (www.sdgltd.com) for regulatory advice and strategic planning with the U.S. Food and Drug Administration (FDA). The Company intends to work in conjunction with the principals of SDG to organize, request, and participate in a planning meeting with the FDA and to prepare the filing of the Company’s investigational new drug application (IND) to allow initiation of human trials for the humanized version of the Company’s lead product Cytolin®.
